C1CCE12B-8892-49AB-8DF2-E5E280DEAE32
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.52431011826544
- age_years
- 28
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.525
- INTERFERON_GAMMA_RESPONSE+0.515
- PROTEIN_SECRETION+0.455
- ALLOGRAFT_REJECTION+0.424
- INFLAMMATORY_RESPONSE+0.412
- TGF_BETA_SIGNALING+0.412
- IL6_JAK_STAT3_SIGNALING+0.400
- NOTCH_SIGNALING+0.400
- COMPLEMENT+0.350
- IL2_STAT5_SIGNALING+0.341
Top 10 suppressed
- KRAS_SIGNALING_DN-0.368
- OXIDATIVE_PHOSPHORYLATION-0.273
- MYOGENESIS-0.268
- PANCREAS_BETA_CELLS-0.267
- SPERMATOGENESIS-0.134
- HEDGEHOG_SIGNALING-0.130
- FATTY_ACID_METABOLISM-0.100
- ESTROGEN_RESPONSE_LATE-0.070
- UV_RESPONSE_UP-0.061
- HYPOXIA-0.056
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.923 |
| 2 | SRR934833 | — | — | 0.903 |
| 3 | SRR934942 | — | — | 0.898 |
| 4 | SRR934832 | — | — | 0.898 |
| 5 | 722B7A0F-BF34-4368-8CFF-944FCBC7DAC4 | — | — | 0.890 |
| 6 | SRR934940 | — | — | 0.889 |
| 7 | SRR934854 | — | — | 0.888 |
| 8 | SRR934807 | — | — | 0.888 |
| 9 | SRR934943 | — | — | 0.886 |
| 10 | E5FB107A-9555-419F-84BF-2A59873104B9 | — | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.525 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.515 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.455 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.424 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.412 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.412 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.341 | Idelalisib | — uncovered |
| APOPTOSIS | 0.296 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.266 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.247 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.239 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.213 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.212 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.203 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.176 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |